Skip to content

The effects of sitaglibtin, glutazone and other glucose lowering drugs on inflammatory and coagulative factors and lipid profile in type 2 diabetes patients

The effects of sitaglibtin, glutazone and other glucose lowering drugs on inflammatory and coagulative factors and lipid profile in type 2 diabetes patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130610013612N9
Enrollment
120
Registered
2018-06-13
Start date
2018-04-30
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus with hyperosmolarity

Interventions

Intervention 1: Intervention group: The first group received 100 mg of sitagliptin daily for 3 months. Intervention 2: Intervention group: The second group received 30 mg of glutathione daily for 3 mo

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 55 Years

Inclusion criteria

Inclusion criteria: Age 45-55 years HbA1C is more than 7 in less than 8. BMI is greater than 25 and less than 30.

Exclusion criteria

Exclusion criteria: Having any cardiovascular, inflammatory, autoimmune disease Taking warfarin Presence of infection

Design outcomes

Primary

MeasureTime frame
High-Sensitivity C-Reactive Protein. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;HDL Cholesterol. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Fibrogen. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.

Secondary

MeasureTime frame
Fast blood sugar. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Cholestrol. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Triglyceride. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Blood Test.;Body Mass Index. Timepoint: Baseline and 3 months after the treatment. Method of measurement: Weigh.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farzad Najafipour

Tabriz University of Medical Sciences

Farzadnajafipour@gmail.com+98 41 3335 7850

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026